# Jeisys Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jeisys-medical

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.jeisys.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Jun 25, 2019)
- Investors on record: 4

## About

Based in Seoul, South Korea, and founded in 2001, Jeisys Medical Inc. operates as a medical device manufacturing company. In August 2019, the firm raised KRW 4 billion in series A funding led by investors BNH Investment, GSA Private Equity, and The Turning Point. As of July 2023, the firm sells its products to plastic surgeons, dermatologists, physicians, and healthcare professionals in America, Europe, the Middle East, Asia, and Oceania region. In September 2024, ARCHIMED, along with the company's management, agreed to acquire a 98.2% majority stake in Jeisys Medical Inc. for KRW 990 billion from The Turning Point, GSA Private Equity, DAYLI Partners, and BNH Investment in a public-to-private transaction.

The global medical technology company specializes in the development and manufacturing of advanced medical and aesthetic treatment products. The range of medical and beauty treatments such as body contouring, skin rejuvenation, pigmentation treatments, hair removal, etc products offered by Jeisys, includes Intense Pulsed Light (IPL) treatment products for acne, CO2 laser, Q-Switch laser, radio frequency (RF) microneedle, and High-intensity focused ultrasound (HIFU) equipment, etc. The company’s flagship product is LIPOcel™, a non-invasive fat reduction system that utilizes HIFU technology. LIPOcel™ delivers thermal energy to target and destroy fat cells, resulting in a reduction in waist, thigh, and arms circumference without the need for surgery.  Additionally, the firm also offers a variety of Medical & Aesthetic treatments including skin rejuvenation, pigmentation, tattoo removal, scars and striae distensae, lifting and tightening, etc treatments.



In 2023, the company generated revenue of KRW 143 billion and operating profit of KRW 36.3 billion.

## Funding rounds

- Series A, Jun 25, 2019, $3.5M — BNH Investment, DAYLI Partners, The Turning Point, GSA Private Equity

## Investors

- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A
- The Turning Point (https://capitalatlas.ai/funds/the-turning-point) — Series A
- GSA Private Equity (https://capitalatlas.ai/funds/gsa-private-equity) — Series A